SEC Form 4 · accession 0001192482-18-000303
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Garry Arthur Neil
Officer — Chief Scientific Officer
Period of report
Jun 14, 2018
Accepted (ET)
Jun 18, 2018 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Purchase)F1,F2 | $1.55 | Jun 14, 2018 | A | 261,000 | A | — | Apr 17, 2028 | Common Stock | 261,000 | 261,000 | D |
Explanation of responses
- F1The option award was granted on April 17, 2018 and was subject to forfeiture if stockholder approval of a proposed amendment to the Issuer's stock incentive plan to increase the number of shares reserved for issuance under the plan was not obtained. The Issuer's stockholders approved the amendment to the Issuer's stock incentive plan at the Issuer's annual meeting of stockholders on June 14, 2018.
- F2The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on April 17, 2019, then in 24 equal monthly installments on the 17th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer.